Tuberculosis Debate
Full Debate: Read Full DebateDepartment: Foreign, Commonwealth & Development Office
Sarah Wollaston
Main Page: Sarah Wollaston (Liberal Democrat - Totnes)Department Debates - View all Sarah Wollaston's debates with the Foreign, Commonwealth & Development Office
(6 years, 6 months ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Nick Herbert
Again, I do agree. The scale of TB in London makes it one of the TB capitals of Europe. We have some 5,000 cases of TB in the UK. That figure is coming down with the new public health strategy, but it is still too high. The right hon. Gentleman is right. This disease is easily and cheaply curable, and it has been since the discovery of antibiotics, so why are we not doing it?
Dr Sarah Wollaston (Totnes) (Con)
I thank my right hon. Friend for his very powerful speech. Further to his points about the importance of public health, would he urge the Government, in their future strategy, to make sure that we look at NHS public health and social care as part of a single system?
Nick Herbert
Yes. My hon. Friend is probably aware that there is a collaborative TB strategy that was introduced by the Government, urged by the all-party parliamentary group on global TB, which the hon. Member for Ealing, Southall and I co-chair. That strategy shows very promising signs. It represents exactly the kind of partnership that we need between Public Health England and NHS England. I commend the Government for having introduced that partnership.
Most people do not realise that there is no vaccine for tuberculosis. There is a child vaccine, BCG, that some of us had when we were young, but there is no adult vaccine that works for tuberculosis—and no epidemic in human history has been beaten without a vaccine. The reason there is no vaccine is that there is market failure. Unlike HIV/AIDS, this is primarily a disease of the poor. With HIV/AIDS, there were people dying in western countries as well. The pharmaceutical companies do not have a commercial incentive to invest in the new tools that we need—better drugs, better diagnostics and a vaccine. Without partnership funding that comes from the Government, and Governments around the world who can afford it, we will not develop these new tools and we will not beat TB in the requisite timeframe.